KH902 fusion protein clinical trials
Also written Conbercept and KH902.
How each study uses KH902 fusion protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KH902 fusion protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 12
Chengdu Kanghong Biotech Co., Ltd. (8) · Ruijin Hospital (2) · Sun Yat-sen University (2) · Shanghai Eye Disease Prevention and Treatment Center (1) · Bojie Hu (1) · RemeGen Co., Ltd. (1) · Tianjin Medical University Eye Hospital (1) · Wang Yusheng (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test KH902 fusion protein.
- Dec 2026Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyNot applicable · Wang Yusheng
Studies
Open first, then newest update. How each study uses KH902 fusion protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity TherapyRecruitingNot applicableWang YushengNCT06717412Written as ConberceptHow we know
- Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab InjectionCompletedNot applicableBojie HuNCT07144865Written as conbercept ophthalmic injection (0.5mg)How we know
- Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic RetinopathyActive, not recruitingPhase 4Shanghai Eye Disease Prevention and Treatment CenterNCT06305143Written as ConberceptHow we know
- Evaluation of RC28-E Injection in Diabetic Macular EdemaCompletedPhase 2RemeGen Co., Ltd.NCT04782115Written as ConberceptHow we know
- Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR PatientsStatus unknownPhase 2Peking University Third HospitalNCT05642793Written as proactive Anti-VEGF (conbercept) useHow we know
- A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT04990271Written as Conbercept ophthalmic injectionHow we know
- Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE)Status unknownNot applicableZhongshan Ophthalmic Center, Sun Yat-sen UniversityNCT04627402Written as Conbercept and TAHow we know
- Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line TherapyStatus unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT04555304Written as KH903 + PaclitaxelHow we know
- Conbercept Injection in Treatment of Severe Proliferative Diabetic RetinopathyCompletedPhase 4Ruijin HospitalNCT02816710Written as ConberceptHow we know
- Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal HaemangiomaStatus unknownEarly Phase 1Sun Yat-sen UniversityNCT03973125Written as conberceptHow we know
- Intravitreal Conbercept After VitrectomyCompletedEarly Phase 1Tianjin Medical University Eye HospitalNCT03426540Written as ConberceptHow we know
- PRP vs PRP+IVC for Severe nPDRStatus unknownNot applicableRuijin HospitalNCT03863535Written as ConberceptHow we know
- Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal HaemangiomaStatus unknownEarly Phase 1Sun Yat-sen UniversityNCT03571282Written as conberceptHow we know
- The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)Status unknownPhase 4Chengdu Kanghong Biotech Co., Ltd.NCT03159884Written as ConberceptHow we know
- Conbercept in Choroidal Neovascularization Secondary to UveitisStatus unknownPhase 2Chongqing Medical UniversityNCT02934841Written as ConberceptHow we know
- Intravitreal Conbercept for Idiopathic Choroidal NeovascularizationStatus unknownPhase 2Jiao MingfeiNCT02857517Written as conberceptHow we know
- Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)Status unknownPhase 3Chengdu Kanghong Biotech Co., Ltd.NCT02194634Written as ConberceptHow we know
- An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)Status unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT02098720Written as ConberceptHow we know
- A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNVStatus unknownPhase 3Chengdu Kanghong Biotech Co., Ltd.NCT01809223Written as conbercept, FixedHow we know
- Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein OcclusionStatus unknownPhase 2Chengdu Kanghong Biotech Co., Ltd.NCT01809236Written as ConberceptHow we know
See all 21 studies that test KH902 fusion protein →
Given beside what is tested · 2 — KH902 fusion protein is usual care or a partner of the new treatment
- Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular DegenerationStatus unknownPhase 4Xiaodong SunNCT02802657Written as ConberceptHow we know
- Initial Versus Delayed PDT Combination With Conbercept in PCVCompletedPhase 4The Eye Hospital of Wenzhou Medical UniversityNCT02821520Written as conberceptHow we know
As the comparator · 1 — what is tested is compared with KH902 fusion protein
Codes
What other systems call KH902 fusion protein · ClinicalTrials.gg INT005241
- MeSH (NLM) C527363KH902 fusion proteinOne source NLM
- UNII (FDA) 1P05PW62F3CONBERCEPTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527363 | KH902 fusion protein | One source NLM |
| UNII (FDA) | 1P05PW62F3 | CONBERCEPT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.